(0.33%) 5 116.86 points
(0.33%) 38 364 points
(0.37%) 15 987 points
(-0.94%) $83.06
(5.56%) $2.03
(0.33%) $2 354.90
(0.46%) $27.66
(4.05%) $959.45
(-0.25%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
@ $22.40
発行日: 13 2月 2024 @ 23:30
リターン: 0.18%
前回のシグナル: 2月 12 - 23:36
前回のシグナル:
リターン: -3.80 %
Live Chart Being Loaded With Signals
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications...
Stats | |
---|---|
本日の出来高 | 355 712 |
平均出来高 | 333 532 |
時価総額 | 613.03M |
EPS | $0 ( 2024-03-13 ) |
次の収益日 | ( $-1.540 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.69 |
ATR14 | $0.0530 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Faga Daniel | Sell | 145 940 | Common Stock |
2024-03-25 | Faga Daniel | Sell | 3 000 | Common Stock |
2024-03-26 | Faga Daniel | Sell | 347 441 | Common Stock |
2024-02-16 | Loumeau Eric J | Sell | 5 000 | Employee Stock Option (right to buy) |
2024-02-16 | Loumeau Eric J | Buy | 5 000 | Common Stock |
INSIDER POWER |
---|
37.37 |
Last 98 transactions |
Buy: 3 215 504 | Sell: 1 263 529 |
ボリューム 相関
AnaptysBio Inc 相関
10 最も負の相関 | |
---|---|
MSDA | -0.938 |
DHAC | -0.929 |
MCAA | -0.928 |
MYRG | -0.92 |
BRIV | -0.918 |
RELY | -0.917 |
SKYA | -0.917 |
BRIVU | -0.916 |
FICV | -0.914 |
ADAL | -0.914 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AnaptysBio Inc 相関 - 通貨/商品
AnaptysBio Inc 財務諸表
Annual | 2023 |
収益: | $17.16M |
総利益: | $14.78M (86.15 %) |
EPS: | $-6.08 |
FY | 2023 |
収益: | $17.16M |
総利益: | $14.78M (86.15 %) |
EPS: | $-6.08 |
FY | 2022 |
収益: | $10.29M |
総利益: | $7.95M (77.30 %) |
EPS: | $-4.57 |
FY | 2021 |
収益: | $63.18M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。